(Q37676223)

21 August 2017

1 reference

title

Investigational therapies for non-muscle invasive bladder cancer (English)

1 reference

21 August 2017

Daniel P Casella

2

1 reference

ORCID Public Data File 2021

author name string

Marc C Smaldone

series ordinal

1

1 reference

21 August 2017

Daniel R Welchons

series ordinal

3

1 reference

21 August 2017

Jeffrey R Gingrich

series ordinal

4

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

1 reference

21 August 2017

19

1 reference

21 August 2017

3

1 reference

21 August 2017

371-383

1 reference

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Clinical model of lifetime cost of treating bladder cancer and associated complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

The invasive T1 bladder tumor: contemporary issues and rationale for radical cystectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Combination of BCG and interferon intravesical immunotherapy: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Risk-adapted use of intravesical immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Current and new strategies in immunotherapy for superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Definition and management of patients with bladder cancer who fail BCG therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Intravesical treatments of bladder cancer: review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

The effect of fasting or desmopressin before treatment on the concentration of mitomycin C during intravesical administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Influence of chitosan and polycarbophil on permeation of a model hydrophilic drug into the urinary bladder wall

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Novel gelatin-adriamycin sustained drug release system for intravesical therapy of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Preliminary European Results of Local Microwave Hyperthermia and Chemotherapy Treatment in Intermediate or High Risk Superficial Transitional Cell Carcinoma of the Bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903563372

10.1517/13543780903563372

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference